Oppenheimer Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80
Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
H.C. Wainwright Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $65
Capital One Financial Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $55
Express News | Jasper Therapeutics: Data From Newly Added 360Mg Single-Dose Cohort Is Expected to Be Reported in H1 2025
Jasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria